Biotech financing update June to August 2020.pdf
The scale of UK biotech fundraising has continued to accelerate in the third quarter of 2020, with a record £1bn raised between 1 June and 31 August. Public markets continue to be the driver of this strong performance.
The first IPO of the year secured £119m on NASDAQ and follow-on financings totalled £601m. Venture capital investment was slightly down on the previous quarter but still healthy at £282m raised, including an uplift in seed and series A financings.
A total of £1.9bn has been raised to date in 2020, meaning it is already the second-best year on record and on target to surpass the annual total of £2.2bn achieved in 2018.